Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
2010 · Journal of Clinical Oncology · 1,577 citations
https://doi.org/10.1200/jco.2010.29.7101
J
Jean-Jacques Body
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
30
Papers
5.5K
Citations
20
h-index
23
i10-index
Jean-Jacques Body is an academic researcher from Centre Hospitalier Universitaire Brugmann. The author has contributed to research in topics: Bone health and treatments & Radiopharmaceutical Chemistry and Applications & Cancer Diagnosis and Treatment. The author has an h-index of 20, co-authored 26 publications.
Papers by this author
worksSafety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
2015 · Supportive Care in Cancer · 187 citations
https://doi.org/10.1007/s00520-015-2904-5
Hypocalcaemia in patients with metastatic bone disease treated with denosumab
2015 · European Journal of Cancer · 144 citations
https://doi.org/10.1016/j.ejca.2015.05.016
Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials
2013 · Journal of bone oncology · 39 citations
https://doi.org/10.1016/j.jbo.2013.01.002
Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG
2025 · Journal of bone oncology · 8 citations
https://doi.org/10.1016/j.jbo.2025.100694
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat